Current treatment status-Not currently treated - Page 2 of 28 Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Posted by on May 8, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data showed that pembrolizumab in combination with rituximab was safe and effective in these patients. Some background Follicular lymphoma (FL)...

Read More

Effects of combined treatment with selinexor, carfilzomib and dexamethasone once a week in patients with relapsed/refractory multiple myeloma

Effects of combined treatment with selinexor, carfilzomib and dexamethasone once a week in patients with relapsed/refractory multiple myeloma

Posted by on Feb 13, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of selinexor (Xpovio) in combination with carfilzomib (Kyprolis) and dexamethasone (Decadron) (XKd) in patients with relapsed/refractory (r/r) multiple myeloma (MM) that still responded to carfilzomib. The data showed that weekly administered XKd was highly effective and...

Read More

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Posted by on Feb 6, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if allogeneic hematopoietic stem cell transplant (alloHSCT) was a suitable treatment strategy for patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) after chimeric antigen receptor (CAR) T-cell therapy.   This study concluded that this was a suitable treatment...

Read More

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Posted by on Dec 31, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in...

Read More

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Posted by on Nov 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL).  This study concluded that this treatment combination was safe and effective in these patients.   Some background HL is a common cancer...

Read More

Evaluating anti-CD25 radioimmunotherapy with BEAM autologous stem cell transplantation in patients with high-risk relapsed or refractory classical Hodgkin lymphoma

Evaluating anti-CD25 radioimmunotherapy with BEAM autologous stem cell transplantation in patients with high-risk relapsed or refractory classical Hodgkin lymphoma

Posted by on Oct 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of 90Y-antiCD25 (yttrium 90 basiliximab; aTac) radioimmunotherapy (RAI), followed by BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapsed or refractory (r/r) classical Hodgkin...

Read More

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) as second-line therapy for patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab plus GVD combination is safe and highly effective...

Read More

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Posted by on Aug 22, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that adding isatuximab to the Kd regimen reduced the risk of disease progression or death for these...

Read More

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Read More

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Posted by on Aug 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the combination of brentuximab vedotin (BV; Adcetris) and ICE salvage chemotherapy with ifosfamide (Ifex), carboplatin (Paraplatin), and etoposide (Etopophos) for the treatment of relapsing or refractory Hodgkin lymphoma (HL). This study showed that BV-ICE was a good salvage treatment option for...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor